FDA Approves Lynparza for Maintenance Treatment of BRCA-Mutant Gynecologic Cancers
December 19, 2018 5:00 pmBy Brielle Benyon
The Food and Drug Administration (FDA) approved Lynparza (olaparib) for the maintenance treatment of adults with deleterious or suspected deleterious germline or somatic BRCA-mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in a
… Read more